Analyst Downgrades: McDonald's Corporation, ACADIA Pharmaceuticals Inc., and Tesla Motors Inc

Analysts downwardly revised their ratings and price targets on McDonald's Corporation (NYSE:MCD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Tesla Motors Inc (NASDAQ:TSLA)

Jun 22, 2016 at 9:14 AM
facebook twitter linkedin

Analysts are weighing in on Dow stock McDonald's Corporation (NYSE:MCD), biotech ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and automaker Tesla Motors Inc (NASDAQ:TSLA). Here's a quick roundup of today's bearish brokerage notes on MCD, ACAD, and TSLA.

  • MCD is 0.9% lower ahead of the open, after Nomura cut its rating to "neutral" from "buy," while slashing its price target to $129 from $142. This is just the latest bout of pessimism thrown toward the stock, as short interest has been surging, and put buying has nearly doubled call buying during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Still, McDonald's Corporation has gained over 26% in the past 12 months to trade at $122.63, while hitting record highs last month. On the news front, the company has reportedly received multiple bids for its China and Hong Kong stores
  • ACAD has dropped more than 2% in electronic trading, after BofA-Merrill Lynch downgraded the stock to "neutral" from "buy." Shares of ACADIA Pharmaceuticals Inc. dropped over 6% yesterday, likely due to sector-wide headwinds, to close at $34.99 -- back in the red for 2016. If ACAD continues to struggle, it could get hit with more downgrades, since six of seven analysts were calling it a "strong buy" coming into today. 
  • TSLA last night offered to buy fellow Elon Musk firm SolarCity Corp (NASDAQ:SCTY) for roughly $2.8 billion -- or $26.50-$28.50 per SCTY share. Musk has deemed the deal a "no brainer," and said he will recuse himself from the shareholders' vote, which has yet to be scheduled. In the meantime, Wall Street hasn't reacted well, with Tesla Motors Inc set to open 11% lower this morning. Moreover, Oppenheimer cut TSLA to "perform" from "outperform," and removed its price target of $385. Based on last night's close at $219.61, the stock was already well below breakeven on a year-to-date basis, and has lagged the broader S&P 500 Index (SPX) by roughly 13 percentage points in the past two months. Nonetheless, call buying has remained hot.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report


Special Offers from Schaeffer's Trading Partners